Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Potential Harms of rhGH Treatment to Patients with CF: Cancer Risk (3)
rhGH-treated patients with CF exhibited increases in IGF-I that were >100 ng/mL. The significance of this result for long-term risk after withdrawal of rhGH is unknown, however, and the level of evidence is insufficient to formulate a summary effect. IGFBP-3 levels were reported to increase during rhGH treatment as well, but only to levels far below the 1,000 ng/mL concentration thought to have significance for cancer risk.
There is insufficient evidence about cancer incidence among patients who do not have CF but have been treated with rhGH for the FDA-approved conditions of growth-hormone deficiency and idiopathic short stature to evaluate risk for patients with CF.
Keywords: IGF-I | insulin-like growth factor | IGFBP-3 | cancer | risk | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.